D

Dhg Pharmaceutical Joint-Stock Co
VN:DHG

Watchlist Manager
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Watchlist
Price: 105 100 VND -0.66% Market Closed
Market Cap: 13.7T VND
Have any thoughts about
Dhg Pharmaceutical Joint-Stock Co?
Write Note
Section:
 

Relative Value

The Relative Value of one DHG stock under the Base Case scenario is 99 397.12 VND. Compared to the current market price of 105 100 VND, Dhg Pharmaceutical Joint-Stock Co is Overvalued by 5%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DHG Relative Value
Base Case
99 397.12 VND
Overvaluation 5%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

2.8
P/S
P/S
Price to Sales
2.8
vs History
63
vs Industry
40
Median 3Y
2.8
Median 5Y
2.8
Industry
2.5
Forward
2.7
More Details
17.1
P/E
P/E
Price to Earnings
17.1
vs History
31
vs Industry
28
Median 3Y
15.8
Median 5Y
15.4
Industry
21.8
Forward
15.2
More Details
13.7
P/OCF
P/OCF
Price to OCF
13.7
vs History
79
vs Industry
18
Median 3Y
18.3
Median 5Y
15.2
Industry
16.1
More Details
11.3
P/FCFE
P/FCFE
Price to FCFE
11.3
vs History
98
vs Industry
16
Median 3Y
24.6
Median 5Y
21.9
Industry
23.8
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
58
vs Industry
27
Median 3Y
3
Median 5Y
3.1
Industry
2.1
More Details
2.4
EV/S
EV/S
Enterprise Value to Sales
2.4
vs History
53
vs Industry
44
Median 3Y
2.4
Median 5Y
2.3
Industry
2.6
Forward
2.3
More Details
5.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.7
vs History
31
vs Industry
39
Median 3Y
5.2
Median 5Y
5
Industry
5.2
More Details
13.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
13.1
vs History
28
vs Industry
29
Median 3Y
11.5
Median 5Y
11.3
Industry
13.8
Forward
12
More Details
14.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.9
vs History
26
vs Industry
30
Median 3Y
12.7
Median 5Y
12.7
Industry
17
Forward
13.5
More Details
12
EV/OCF
EV/OCF
Enterprise Value to OCF
12
vs History
76
vs Industry
22
Median 3Y
15.9
Median 5Y
12.7
Industry
15.3
More Details
14.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
14.3
vs History
58
vs Industry
3
Median 3Y
15.4
Median 5Y
14.3
Industry
19.2
More Details
3.8
EV/IC
EV/IC
Enterprise Value to IC
3.8
vs History
82
vs Industry
22
Median 3Y
3.8
Median 5Y
4
Industry
1.9
More Details

Multiples Across Competitors

DHG Competitors Multiples
Dhg Pharmaceutical Joint-Stock Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
13.7T VND 2.8 17.1 13.1 14.9
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
743.9B USD 18.2 88.9 47.8 53.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 10.4 29.7 20.6 23.5
US
Johnson & Johnson
NYSE:JNJ
349.2B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
252.4B USD 4 20.8 10.5 12.6
CH
Roche Holding AG
SIX:ROG
202.2B CHF 3.4 17.6 9.9 11.8
UK
AstraZeneca PLC
LSE:AZN
162.2B GBP 4.2 31.7 169.4 253.9
CH
Novartis AG
SIX:NOVN
173.8B CHF 3.9 10.9 9.5 13.2
US
Pfizer Inc
NYSE:PFE
150.9B USD 2.5 35.5 10.6 15.9
P/E Multiple
Earnings Growth PEG
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average P/E: 30.7
17.1
1%
17.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
88.9
76%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29.7
23%
1.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-8%
N/A
US
Merck & Co Inc
NYSE:MRK
20.8
320%
0.1
CH
Roche Holding AG
SIX:ROG
17.6
15%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.7
40%
0.8
CH
Novartis AG
SIX:NOVN
10.9
9%
1.2
US
Pfizer Inc
NYSE:PFE
35.5
102%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average EV/EBITDA: 414.9
13.1
2%
6.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
43%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.6
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.5
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
UK
AstraZeneca PLC
LSE:AZN
169.4
18%
9.4
CH
Novartis AG
SIX:NOVN
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average EV/EBIT: 1 811.6
14.9
1%
14.9
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
46%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.5
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
15
9%
1.7
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
11.8
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
253.9
32%
7.9
CH
Novartis AG
SIX:NOVN
13.2
17%
0.8
US
Pfizer Inc
NYSE:PFE
15.9
19%
0.8

See Also

Summary
DHG intrinsic value, competitors valuation, and company profile.
DCF Valuation
DHG stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DHG stock valuation using valuation multiples.
Wall Street Estimates
DHG price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DHG stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 211,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.